tiprankstipranks
Protara Therapeutics (TARA)
NASDAQ:TARA
US Market
TARA
Protara Therapeutics
RESEARCH TOOLSreports

Protara Therapeutics (TARA) Stock Forecast & Price Target

1,386 Followers
See the Price Targets and Ratings of:

TARA Analyst Ratings

Strong Buy
7Ratings
Strong Buy
7 Buy
0 Hold
0 Sell
Based on 7 analysts giving stock ratings to
Protara
Therapeutics
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

TARA Stock 12 Month Forecast

Average Price Target

$26.00
▲(398.08% Upside)
Based on 7 Wall Street analysts offering 12 month price targets for Protara Therapeutics in the last 3 months. The average price target is $26.00 with a high forecast of $30.00 and a low forecast of $23.00. The average price target represents a 398.08% change from the last price of $5.22.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"2":"$2","31":"$31","9.25":"$9.25","16.5":"$16.5","23.75":"$23.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":30,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$30.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":26,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$26.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":23,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$23.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[2,9.25,16.5,23.75,31],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jun<br/>2025","6":"Oct<br/>2025","9":"Jan<br/>2026","12":"Apr<br/>2026","25":"Apr<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,5.04,6.96,8.88,10.8,12.72,14.64,16.560000000000002,18.48,20.400000000000002,22.32,24.240000000000002,26.16,28.080000000000002,{"y":30,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,5.04,6.6523076923076925,8.264615384615386,9.876923076923077,11.489230769230769,13.10153846153846,14.713846153846156,16.326153846153847,17.93846153846154,19.55076923076923,21.163076923076922,22.775384615384617,24.38769230769231,{"y":26,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,5.04,6.421538461538462,7.803076923076923,9.184615384615384,10.566153846153846,11.947692307692307,13.329230769230769,14.71076923076923,16.092307692307692,17.473846153846154,18.855384615384615,20.236923076923077,21.61846153846154,{"y":23,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":3.74,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.01,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.46,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.3,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.06,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.17,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.41,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.18,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.74,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.33,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 32, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.04,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 32, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.97,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 49, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.04,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 18, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$30.00Average Price Target$26.00Lowest Price Target$23.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
JonesTrading Analyst forecast on TARA
Soumit Roy
JonesTrading
JonesTrading
$25
Buy
378.93%
Upside
Reiterated
04/06/26
JonesTrading Remains a Buy on Protara Therapeutics (TARA)
Piper Sandler Analyst forecast on TARA
Kelsey Goodwin
Piper Sandler
Piper Sandler
―
Buy
―
Reiterated
03/26/26
Wall Street Analysts Are Bullish on Top Healthcare Picks
LifeSci Capital Analyst forecast on TARA
Charles Zhu
LifeSci Capital
LifeSci Capital
$26
Buy
398.08%
Upside
Assigned
03/21/26
Buy Rating on TARA-002 Backed by Best-in-Class NMIBC Data, FDA-Aligned Phase 3 Strategy, and Solid Cash Runway
J.P. Morgan Analyst forecast on TARA
Brian Cheng
J.P. Morgan
J.P. Morgan
$27
Buy
417.24%
Upside
Reiterated
03/12/26
J.P. Morgan Sticks to Its Buy Rating for Protara Therapeutics (TARA)
H.C. Wainwright Analyst forecast on TARA
Andres Y. Maldonado
H.C. Wainwright
H.C. Wainwright
$23
Buy
340.61%
Upside
Reiterated
03/11/26
Analysts' Top Healthcare Picks: Protara Therapeutics (TARA), Viridian Therapeutics (VRDN)
Oppenheimer Analyst forecast on TARA
Unknown Analyst
Oppenheimer
Not Ranked
Oppenheimer
$25
Buy
378.93%
Upside
Reiterated
03/11/26
Protara Therapeutics (TARA) Receives a Buy from Oppenheimer
TD Cowen Analyst forecast on TARA
Stacy Ku
TD Cowen
TD Cowen
$50→$30
Buy
474.71%
Upside
Reiterated
02/23/26
Analysts Offer Insights on Healthcare Companies: Beam Therapeutics (NASDAQ: BEAM), Protara Therapeutics (NASDAQ: TARA) and Kiniksa Pharmaceuticals (NASDAQ: KNSA)
Scotiabank Analyst forecast on TARA
George Farmer
Scotiabank
Scotiabank
$12
Buy
129.89%
Upside
Reiterated
05/09/25
Protara Therapeutics (TARA) Gets a Buy from Scotiabank
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
JonesTrading Analyst forecast on TARA
Soumit Roy
JonesTrading
JonesTrading
$25
Buy
378.93%
Upside
Reiterated
04/06/26
JonesTrading Remains a Buy on Protara Therapeutics (TARA)
Piper Sandler Analyst forecast on TARA
Kelsey Goodwin
Piper Sandler
Piper Sandler
―
Buy
―
Reiterated
03/26/26
Wall Street Analysts Are Bullish on Top Healthcare Picks
LifeSci Capital Analyst forecast on TARA
Charles Zhu
LifeSci Capital
LifeSci Capital
$26
Buy
398.08%
Upside
Assigned
03/21/26
Buy Rating on TARA-002 Backed by Best-in-Class NMIBC Data, FDA-Aligned Phase 3 Strategy, and Solid Cash Runway
J.P. Morgan Analyst forecast on TARA
Brian Cheng
J.P. Morgan
J.P. Morgan
$27
Buy
417.24%
Upside
Reiterated
03/12/26
J.P. Morgan Sticks to Its Buy Rating for Protara Therapeutics (TARA)
H.C. Wainwright Analyst forecast on TARA
Andres Y. Maldonado
H.C. Wainwright
H.C. Wainwright
$23
Buy
340.61%
Upside
Reiterated
03/11/26
Analysts' Top Healthcare Picks: Protara Therapeutics (TARA), Viridian Therapeutics (VRDN)
Oppenheimer Analyst forecast on TARA
Unknown Analyst
Oppenheimer
Not Ranked
Oppenheimer
$25
Buy
378.93%
Upside
Reiterated
03/11/26
Protara Therapeutics (TARA) Receives a Buy from Oppenheimer
TD Cowen Analyst forecast on TARA
Stacy Ku
TD Cowen
TD Cowen
$50→$30
Buy
474.71%
Upside
Reiterated
02/23/26
Analysts Offer Insights on Healthcare Companies: Beam Therapeutics (NASDAQ: BEAM), Protara Therapeutics (NASDAQ: TARA) and Kiniksa Pharmaceuticals (NASDAQ: KNSA)
Scotiabank Analyst forecast on TARA
George Farmer
Scotiabank
Scotiabank
$12
Buy
129.89%
Upside
Reiterated
05/09/25
Protara Therapeutics (TARA) Gets a Buy from Scotiabank
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
xxx
xxx
xxx
xxx
xxx
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Protara Therapeutics

3 Months
xxx
Success Rate
4/9 ratings generated profit
44%
Average Return
+16.77%
reiterated a xxx
 rating last month
Copying xxxxxxxxxxxxxxxxxx
 trades and holding each position for 3 Months would result in 44.44% of your transactions generating a profit, with an average return of +16.77% per trade.
1 Year
Andres Y. MaldonadoH.C. Wainwright
Success Rate
6/9 ratings generated profit
67%
Average Return
+25.08%
reiterated a buy rating last month
Copying Andres Y. Maldonado's trades and holding each position for 1 Year would result in 66.67% of your transactions generating a profit, with an average return of +25.08% per trade.
2 Years
xxx
Success Rate
6/9 ratings generated profit
67%
Average Return
+25.08%
reiterated a xxx
 rating last month
Copying xxxxxxxxxxxxxxxxxx
 trades and holding each position for 2 Years would result in 66.67% of your transactions generating a profit, with an average return of +25.08% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

TARA Analyst Recommendation Trends

Rating
Dec 25
Jan 26
Feb 26
Mar 26
Apr 26
Strong Buy
17
18
16
17
13
Buy
0
1
1
2
1
Hold
1
32
32
49
18
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
18
51
49
68
32
In the current month, TARA has received 14 Buy Ratings, 18 Hold Ratings, and 0 Sell Ratings. TARA average Analyst price target in the past 3 months is 26.00.
Each month's total comprises the sum of three months' worth of ratings.

TARA Financial Forecast

TARA Earnings Forecast

Next quarter’s earnings estimate for TARA is -$0.35 with a range of -$0.41 to -$0.24. The previous quarter’s EPS was -$0.37. TARA beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.87% of the time in the same period. In the last calendar year TARA has Performed in-line its overall industry.
Next quarter’s earnings estimate for TARA is -$0.35 with a range of -$0.41 to -$0.24. The previous quarter’s EPS was -$0.37. TARA beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.87% of the time in the same period. In the last calendar year TARA has Performed in-line its overall industry.
No data currently available

TARA Sales Forecast

Next quarter’s sales forecast for TARA is $0.00 with a range of $0.00 to $0.00. The previous quarter’s sales results were $0.00. TARA beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.06% of the time in the same period. In the last calendar year TARA has Performed in-line its overall industry.
Next quarter’s sales forecast for TARA is $0.00 with a range of $0.00 to $0.00. The previous quarter’s sales results were $0.00. TARA beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.06% of the time in the same period. In the last calendar year TARA has Performed in-line its overall industry.

TARA Stock Forecast FAQ

What is TARA’s average 12-month price target, according to analysts?
Based on analyst ratings, Protara Therapeutics’s 12-month average price target is 26.00.
    What is TARA’s upside potential, based on the analysts’ average price target?
    Protara Therapeutics has 398.08% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is TARA a Buy, Sell or Hold?
          Protara Therapeutics has a consensus rating of Strong Buy which is based on 7 buy ratings, 0 hold ratings and 0 sell ratings.
            What is Protara Therapeutics’s price target?
            The average price target for Protara Therapeutics is 26.00. This is based on 7 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst price target is $30.00 ,the lowest forecast is $23.00. The average price target represents 398.08% Increase from the current price of $5.22.
              What do analysts say about Protara Therapeutics?
              Protara Therapeutics’s analyst rating consensus is a Strong Buy. This is based on the ratings of 7 Wall Streets Analysts.
                How can I buy shares of TARA?
                Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.